5 Myeloproliferative Neoplasms Clinical Trials in Ann Arbor, MI (2026)

Q: How do I join a clinical trial in Ann Arbor?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Ann Arbor research site will contact you.

Recruiting Myeloproliferative Neoplasms Studies in Ann Arbor

NCT01973881Recruiting

Quantitative MRI for Myelofibrosis

This study is for the development and validation of functional magnetic resonance imaging (MRI) parameters as biomarkers for analyzing extent of disease and quantifying response to treatment in patien...

Ann Arbor, MI192 participantsUniversity of Michigan Rogel Cancer Center

View Study Details

NCT06313593Recruiting

A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms

This study is being conducted to assess the Safety, Tolerability, and Pharmacokinetics of INCB160058 in Participants With Myeloproliferative Neoplasms....

Ann Arbor, MIPHASE1186 participantsIncyte Corporation

View Study Details

NCT05320198Recruiting

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

This phase 1b/2a open-label study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DISC-0974 as well as categorize the effects on anemia response in subjects with myelofi...

Ann Arbor, MIPHASE1150 participantsDisc Medicine, Inc

View Study Details

NCT06343805Recruiting

A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

AJX-101 is a first-in-human (FIH), phase 1, non-randomized, multi-center, open-label clinical trial designed to investigate the safety, tolerability, pharmacokinetics (PK), clinical activity and chang...

Ann Arbor, MIPHASE176 participantsAjax Therapeutics, Inc.

View Study Details

NCT06517875Recruiting

Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis

The purpose of this Phase 2 study is to evaluate the efficacy and safety of momelotinib (MMB) in combination with luspatercept (LUSPA) in participants with transfusion dependence (TD) primary myelofib...

Ann Arbor, MIPHASE268 participantsGlaxoSmithKline

View Study Details

About Myeloproliferative Neoplasms Clinical Trials in Ann Arbor

Myeloproliferative neoplasms (MPNs) are blood cancers in which the bone marrow overproduces red blood cells, platelets, or white blood cells. Types include polycythemia vera, essential thrombocythemia, and myelofibrosis. Treatment depends on the specific type and risk factors.

There are currently 5 myeloproliferative neoplasms clinical trials recruiting participants in Ann Arbor, MI. These studies are seeking a combined 672 participants. Research is being sponsored by University of Michigan Rogel Cancer Center, Incyte Corporation, Disc Medicine, Inc and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Myeloproliferative Neoplasms Clinical Trials in Ann Arbor — FAQ

Are there myeloproliferative neoplasms clinical trials in Ann Arbor?

Yes, there are 5 myeloproliferative neoplasms clinical trials currently recruiting in Ann Arbor, MI. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Ann Arbor?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Ann Arbor research site will contact you about next steps.

Are clinical trials in Ann Arbor free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Ann Arbor studies also compensate for your time and travel.

What myeloproliferative neoplasms treatments are being tested?

The 5 active trials in Ann Arbor are testing new therapies including novel drugs, biologics, and treatment approaches for myeloproliferative neoplasms.

Data updated July 18, 2026 from ClinicalTrials.gov